Unravel Data Named a Cool Vendor by Gartner in Performance Analysis; Analytics and Containers
The News Follows Unravel’s Introduction of New Artificial Intelligence for IT Operations (AIOps) Capabilities for Automated Performance Tuning of Big Data Applications
PALO ALTO, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Unravel Data, the application performance management (APM) platform designed for big data applications, today announced it has been named a 2018 Cool Vendor by leading research and advisory firm Gartner in the report titled, “Cool Vendors in Performance Analysis; Analytics and Containers.”
Gartner conducts its Cool Vendor research annually. Gartner's Cool Vendor research is designed to highlight interesting, new and innovative vendors, products and services.
For this report, Gartner identified five companies that are leading the market with innovative approaches that I&O leaders can use to address challenges presented by containerization, cloud and microservices.
According to Gartner, “I&O leaders focused on IT operations transformation should: Prepare for their IT environment’s future state and monitoring needs by implementing container- and microservices-ready monitoring tools; Evaluate the vendors in this research by comparing their offerings and ability to deliver insight with those of your current monitoring portfolio; Improve visibility into DevOps and developer teams’ environments by embedding monitoring technologies like those examined in this research early in the development cycle.”
Unravel is the industry’s only APM platform designed for big data. Enterprises across financial, telecom, healthcare, technology and other industries leverage Unravel to operationalize their big data stack and improve reliability of applications and productivity of big data teams while reducing cost of ownership.
Unravel was founded in 2014 and so far in 2018 alone has supported more than 10,000 big data nodes and more than 50 million big data applications at Fortune 1000 companies, such as Kaiser Permanente, Leidos, Autodesk and Microsoft. With the market maturation of how big data investments are being monetized and with cloud migration requirements driving the need to support multi-cloud and hybrid workloads, Unravel delivers innovative AIOps capabilities, broad systems support, and interoperability to drive major efficiency gains and competitive agility for enterprises.
“Unravel Data was founded off the back of first-hand experience with the frustration of manually troubleshooting performance problems in big data stacks,” commented Kunal Agarwal, CEO of Unravel Data. “Today, we’re helping enterprises solve their big data problems around cost optimization, service level agreement guarantees, and proactive monitoring and automated remediation so that they spend less time firefighting issues. From our view, recognition from Gartner as a Cool Vendor is very exciting, validates our work, and underscores the momentum we have as we reimagine big data and change the way our customers transform to being data-driven and insight-led.”
A complimentary copy of the “Cool Vendors in Performance Analysis; Analytics and Containers” (Padraig Byrne, Vivek Bhalla, et al., 12 September 2018) report can be downloaded here.
@Gartner_inc named @unraveldata a Cool Vendor in performance analysis, analytics and containers https://ctt.ac/oesBL+ #BigData #APM #DataOps
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About Unravel Data
Unravel Data provides the only Application Performance Management (APM) solution for Big Data. Unravel doesn’t just monitor and unify system-level data, but also tracks, correlates, and interprets performance data across the full-stack in-order to optimize, troubleshoot, and analyze from a single pane. Customers include leading Big Data practitioners such as Kaiser Permanente, Leidos, Autodesk and YP.com. Unravel Data was founded by Kunal Agarwal and Dr. Shivnath Babu when they experienced the frustration of manually troubleshooting performance problems in Big Data stacks firsthand. Unravel’s founding team includes Big Data experts from companies such as Cloudera, Oracle, and Microsoft. Unravel Data has raised a total of $23 million of funding from Menlo Ventures, GGV Capital, M12, Data Elite Ventures and Jyoti Bansal.
The name Unravel Data is a trademark of Unravel Data™. Other trade names used in this document are the properties of their respective owners.
Jordan Tewell, 10Fold
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
VBI Vaccines to Host Conference Call Tomorrow to Review PROTECT Phase 3 Clinical Data for Sci-B-Vac®16.6.2019 18:00:00 CEST | Pressemelding
CAMBRIDGE, Mass., June 16, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, will host a conference call and webcast tomorrow morning, June 17, 2019, at 8:00 AM ET. Management looks forward to reviewing top-line data from PROTECT, one of two pivotal Phase 3 studies for Sci-B-Vac®, the company’s trivalent hepatitis B vaccine. Conference Call and Webcast Details The live webcast and slide presentation can be accessed via the Events/Presentations page in the investors section of the company’s website, https://www.vbivaccines.com/investors/events-presentations/, or by clicking this link: https://edge.media-server.com/m6/p/7ryhzgu2. A replay of the webcast will be archived on the company’s website for 90 days following the live conference call. To listen to the live conference call, please dial: - Toll-free U.S. & Canada Dial-In: (866) 602-1050 - Internat
Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress15.6.2019 16:00:00 CEST | Pressemelding
CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced updated data from its Phase 2 PLAUDIT study of APL-2 in patients with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA). Data from the PLAUDIT trial will be presented in an oral presentation today at the 24th Annual Congress of the European Hematology Association (EHA), held in Amsterdam, the Netherlands. In the ongoing PLAUDIT study, 13 patients with CAD have been enrolled to receive subcutaneous APL-2 treatment, of which 10 patients have been on APL-2 for at least 168 days. The trial has also enrolled 11 patients with wAIHA, 8 of which were Direct Antiglobulin Test (DAT) C3+ (C3+ wAIHA); 5 of the C3+ wAIHA patients
Carpenter Technology and BMT Aerospace Combine Expertise in Redesign and Production of Additively Manufactured Aerospace Component14.6.2019 15:17:00 CEST | Pressemelding
LE BOURGET, France, June 14, 2019 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE:CRS) and Belgium-based BMT Aerospace today announced their cooperation in the development of an additively manufactured (AM) aerospace pinion, using Carpenter Technology’s Custom 465® Stainless. BMT Aerospace and its subsidiary BMT Additive initiated the project by partnering with Carpenter Technology to produce a redesigned pinion. The redesign project was initiated to enable the benefits of additive manufacturing using high quality, printable material that would attain the high-performance expectations for the application. “BMT Aerospace strongly believes in the disruptive potential of additive manufacturing and its possibilities in aerospace,” explained Ewald Goossens, Business Unit Manager of BMT Additive. “As a small player in the market, we strongly believe in cooperation opportunities like these, where each partner can rely and build on a project, starting from its own expertise. Our spe
Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors14.6.2019 13:00:00 CEST | Pressemelding
Collaboration will Combine Immunophotonics’ Proprietary Drug, IP-001, and CLS’s TRANBERG Laser Thermal Therapy System and imILT Method ST. LOUIS and LUND, Sweden, June 14, 2019 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. and Clinical Laserthermia Systems, AB (STO:CLS B) (CLS) today announced they have entered into a research collaboration agreement to support a Phase 1b/2a clinical trial for cancer patients with certain solid tumor indications. The research will utilize each company’s respective products and methodologies during treatments and is intended to support early phase clinical trials facilitated by a leading clinical organization. Eligible patients with solid tumors will be treated using the locally administered CLS Immunostimulating Interstitial Laser Thermotherapy (imILT) method, followed immediately by an intratumoral injection of Immunophotonics’ lead asset, IP-001. Under the agreement, the CLS TRANBERG Laser and single-use products will be used in eligible patients enrolle
iCAD Introduces ProFound AI™ for 2D Mammography in Europe13.6.2019 14:00:00 CEST | Pressemelding
Company to showcase its newest artificial intelligence software solution, ProFound AI for 2D Mammography, in addition to ProFound AI for Digital Breast Tomosynthesis at the SIFEM Medical Conference in France NASHUA, N.H. and LILLE, France, June 13, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the launch of ProFound AI™ for 2D Mammography in Europe. This software is the latest addition to iCAD’s deep-learning, artificial intelligence platform and follows the launch of ProFound AI™ for Digital Breast Tomosynthesis (DBT), which was CE Marked in March 2018 and FDA cleared in December 2018. ProFound AI for 2D Mammography and ProFound AI for DBT will both be featured in the iCAD exhibition booth (#24) at the Société Française d'Imagerie de la FEMme (SIFEM) medical conference from June 13-15, 2019 at the Grand Palais in Lille, France. “iCAD is at the forefront of the fight ag
Telix Pharmaceuticals and Eczacıbaşı-Monrol Sign Manufacturing and Distribution Agreement13.6.2019 13:54:00 CEST | Pressemelding
MELBOURNE, Australia and ISTANBUL, Turkey, June 13, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR) has today announced that it has concluded a master services and distribution agreement with Eczacıbaşı-Monrol. Under the terms of the agreement, Telix has appointed Eczacıbaşı-Monrol as a radiopharmaceutical production partner and distributor in Turkey/Middle East/North Africa. Eczacıbaşı-Monrol is commercially active in more than 40 countries, including important growth territories that complement Telix’s current commercial strategy for the US and Europe. The parties will initially focus on the production and distribution of TLX250-CDx (89Zr-girentuximab) for imaging of renal cell carcinoma with Positron Emission Tomography (PET), including to support the ad